Search research articles
Contact Us
Filters
Showing results (11-20 of 80) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitors
Russell W Jenkins, David A Barbie, Keith T Flaherty
STAR Protocols
|
December 20, 2025
Protocol for the preparation and analysis of patient-derived organotypic tumor spheroids
Claire A Palin, Russell W Jenkins, Or-Yam Revach
The Journal of Cell Biology
|
April 23, 2008
Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway
Youssef H Zeidan, Russell W Jenkins, Yusuf A Hannun
British Journal of Pharmacology
|
May 28, 2011
Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases
Daniel Canals, David M Perry, Russell W Jenkins, et al.
Annual Review of Medicine
|
November 4, 2017
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell W Jenkins, Rohit Thummalapalli, Jacob Carter, et al.
Lab on a Chip
|
June 13, 2025
Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems
David J Bozym, David X Zheng, Or-Yam Revach, et al.
Expert Opinion on Therapeutic Targets
|
August 8, 2025
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer
Giulia Cattaneo, Marco Ventin, Luke Maggs, et al.
Plos One
|
June 15, 2017
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase
Aiping Bai, Cungui Mao, Russell W Jenkins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
August 19, 2007
A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury
Youssef H Zeidan, Bill X Wu, Russell W Jenkins, et al.
American Journal of Clinical Dermatology
|
December 5, 2024
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
David X Zheng, David J Bozym, Giuseppe Tarantino, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 80) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitors
Russell W Jenkins, David A Barbie, Keith T Flaherty
STAR Protocols
|
December 20, 2025
Protocol for the preparation and analysis of patient-derived organotypic tumor spheroids
Claire A Palin, Russell W Jenkins, Or-Yam Revach
The Journal of Cell Biology
|
April 23, 2008
Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway
Youssef H Zeidan, Russell W Jenkins, Yusuf A Hannun
British Journal of Pharmacology
|
May 28, 2011
Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases
Daniel Canals, David M Perry, Russell W Jenkins, et al.
Annual Review of Medicine
|
November 4, 2017
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell W Jenkins, Rohit Thummalapalli, Jacob Carter, et al.
Lab on a Chip
|
June 13, 2025
Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems
David J Bozym, David X Zheng, Or-Yam Revach, et al.
Expert Opinion on Therapeutic Targets
|
August 8, 2025
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer
Giulia Cattaneo, Marco Ventin, Luke Maggs, et al.
Plos One
|
June 15, 2017
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase
Aiping Bai, Cungui Mao, Russell W Jenkins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
August 19, 2007
A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury
Youssef H Zeidan, Bill X Wu, Russell W Jenkins, et al.
American Journal of Clinical Dermatology
|
December 5, 2024
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
David X Zheng, David J Bozym, Giuseppe Tarantino, et al.
Page
of 8